[Attractiveness of paroxysmal nocturnal hemoglobinuria for study].
Hideki
H
Nakakuma
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants / Q000627:therapeutic use; D003676:Deferoxamine / Q000627:therapeutic use; D006242:Haptoglobins / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006457:Hemoglobinuria, Paroxysmal / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008565:Membrane Proteins / Q000235:genetics / Q000502:physiology; D009154:Mutation; D011379:Prognosis
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants; D006242:Haptoglobins; D007166:Immunosuppressive Agents; D008565:Membrane Proteins; C080086:phosphatidylinositol glycan-class A protein; C481642:eculizumab; D003676:Deferoxamine